The Bet Establishment Labs Holders Made

For Establishment Labs shareholders, the return over the past year was 25.2%, including dividends. If you had been weighing an entry on 16 October 2025, you were staring at two sharply different stories. One side leaned on surgeon uptake, new minimally invasive procedures and an affluent patient base. The other flagged cultural shifts, tighter regulation and heavy spending. Which of those forces looked more convincing with only that information in hand?

Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.

Establishment Labs has already moved. See which of 33 high quality undervalued stocks still trade below our estimates.

The Two Establishment Labs Stories Investors Had To Weigh

The shares cost US$46.59 at the start of the period, and Establishment Labs sat between two well defined stories about what might come next.

On the optimistic side, the bull narrative put Fair Value at US$56.07, built on surgeons steadily adopting Motiva implants and new minimally invasive procedures like Preservé to reach a broader, affluent patient pool.

The more cautious view set Fair Value at US$40 and focused on risks such as rising body positivity movements and tighter rules on synthetic implants limiting long run demand for cosmetic surgery.

What The Evidence Around Establishment Labs Actually Tested

The clearest new fact was Establishment Labs securing a US$300 million term loan from Oaktree Capital, which supported the bullish view on funding growth but came with tighter covenants that echoed the cautious focus on risk. Reported Q2 2026 numbers showed revenue up to US$67.5 million and the net loss narrowing to US$11.7 million. Profitability remained unproven, so the evidence cut both ways.

The hinge assumption here was that growth and new procedures would translate into healthier cash generation. For any similar stock, track revenue, net margin and free cash flow together rather than assuming adoption stories alone fix the income statement.

What Establishment Labs’ Recent Gain Already Prices In

Establishment Labs now trades at US$59.18, after a 25.2% gain over the past year. The selected Narrative places Fair Value above that level, reflecting confidence that the current product cycle and market share story still has room to play out.

That view leans heavily on continued surgeon adoption, a broader Motiva and Preservé rollout, and expanding U.S. and international demand. The key question is whether sustained margin progress from higher mix U.S. procedures can support the higher figure the Narrative outlines.

"Several firms highlight that the company is in a new product cycle, particularly in reconstruction surgery, and that its minimally invasive portfolio could appeal to a wider group of surgeons. Some research also points to possible expansion of the overall breast augmentation market if these products see broader adoption."

One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all

Which Company Could Surprise You Next?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 47% below our estimate - uses proprietary betting tech to convert online players into higher margin gaming.
• Company 2 - 46% below our estimate - converts a construction backlog into long duration data center and modular build work.
• Company 3 - 42% below our estimate - sells science and engineering expertise when regulators and courts demand technical clarity.

Three companies from the same screener. Open every one of the 25 solid balance sheet companies →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com